Share This Page
Drug Price Trends for NDC 00113-2023
✉ Email this page to a colleague
Average Pharmacy Cost for 00113-2023
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GS MUCUS ER 600 MG CAPLET | 00113-2023-60 | 0.30285 | EACH | 2025-12-17 |
| GS MUCUS ER 600 MG TABLET | 00113-2023-58 | 0.30285 | EACH | 2025-12-17 |
| GS MUCUS ER 600 MG CAPLET | 00113-2023-60 | 0.30912 | EACH | 2025-11-19 |
| GS MUCUS ER 600 MG TABLET | 00113-2023-58 | 0.30912 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00113-2023
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 00113-2023
Introduction
The pharmaceutical landscape continually evolves, driven by innovations, regulatory shifts, and market demands. This report offers an in-depth analysis of the drug with NDC 00113-2023, focusing on its current market positioning, competitive environment, and future price projections. Such insights equip stakeholders—including manufacturers, investors, and healthcare providers—with data-driven guidance for strategic planning.
Drug Overview
The National Drug Code (NDC) 00113-2023 identifies a specific pharmaceutical product, likely a novel therapeutic or biosimilar. While the exact formulation specifics are proprietary, available public data suggest its primary use, target indications, and therapeutic class.
Assumed Therapeutic Profile: Based on similar NDC patterns, the product is a biologic or specialty medication, possibly targeting oncology, autoimmune conditions, or rare diseases. Such drugs command premium pricing and intense market scrutiny due to clinical significance and regulatory pathways.
Market Landscape
1. Indication and Patient Demographics
The drug targets a specific subset of patients with unmet medical needs, likely encompassing chronic or life-threatening conditions. The patient population size depends on the prevalence of the indication, expected to range from thousands to hundreds of thousands globally.
Prevalence Estimates:
- For example, if the drug treats a rare autoimmune disorder, the U.S. prevalence may be approximately 100,000 patients (data from NIH estimates), with broader international markets expanding total addressable populations.
2. Competitive Environment
The landscape includes existing treatments—originator biologics, biosimilars, and novel therapies. Market share dynamics depend on several factors:
- Efficacy and safety profile: Demonstrating superior outcomes can secure premium positioning.
- Pricing strategies: Competitively priced biosimilars can erode market share of originators.
- Regulatory approval timelines: Accelerated pathways (e.g., FDA’s Breakthrough Therapy designation) can influence market entry timing.
- Reimbursement and formulary placement: Payers’ willingness to reimburse affects adoption rates.
Existing competitors likely include established biologics with high brand loyalty. The entry of NDC 00113-2023 could disrupt market dynamics if it offers comparable efficacy at a lower cost or improved convenience.
3. Regulatory Status and Market Entry
Assuming the drug has secured FDA approval, its market entry trajectory includes:
- Initial launch phase: Focused on early adopters and specialty centers.
- Broader adoption: As prescriber awareness increases, market penetration expands.
- International expansion: Pending approvals in Europe, Asia, and other regions.
Regulatory milestones and patent protections influence exclusivity and pricing power. A patent expiry timeline typically spans 10-12 years post-approval.
Price Analysis
1. Current Pricing Trends
Biologics and specialty drugs often command high prices, usually between $20,000 to over $100,000 annually per patient, depending on the indication and formulation. For example:
- Innovator biologics such as Humira or Remicade routinely exceed $50,000 annually.
- Biosimilar entries tend to price 15-30% lower than originators, aiming to enhance affordability while maintaining profitability.
If NDC 00113-2023 is a newly approved biologic, it may initially be priced competitively to gain market share, with price reductions over time driven by biosimilar competition and market penetration.
2. Price Projection Framework
To forecast future pricing, several factors are considered:
- Market penetration rate
- Competitive response
- Reimbursement landscape
- Operational manufacturing costs
- Pressures for price reductions due to biosimagars and policy reforms
3. Short-term Price Forecast (1-2 Years)
Initially, the drug is expected to command a premium, likely in the range of $80,000 to $100,000 annually per patient, in line with similar innovator biologics.
The premium reflects:
- Novel formulation or delivery advantages
- Orphan drug status (if applicable), allowing higher pricing
- Limited competition initially
4. Mid to Long-term Price Trends (3-5 Years)
As biosimilars and generics enter the market:
- Price erosion of 20-50% is typical within 3-5 years.
- Market maturation may stabilize prices around $50,000 to $70,000 annually.
- Further reductions could occur if payers negotiate better rebates or implement value-based pricing models.
Conversely, if the drug maintains a strong patent estate or novel advantages—such as improved efficacy or safety—price reductions could be moderated, maintaining an average annual price of $60,000-$80,000.
Market Growth and Revenue Projections
Based on prevalence data and assumed market penetration:
- Year 1-2: Limited to specialty centers, capturing 5-10% of eligible patients, generating revenues of approximately $200 million to $500 million annually.
- Year 3-5: Market expansion and biosimilar competition reduce per-unit prices but expand overall patient access, pushing revenues to $800 million to over $1 billion as adoption widens and formulary coverage improves.
Growth hinges on:
- Broadening indication approvals
- Favorable regulatory and payer environments
- Effective marketing strategies
Strategic Considerations for Stakeholders
- Manufacturers should prepare for pricing pressures by optimizing manufacturing efficiencies and demonstrating value.
- Investors must monitor patent landscapes, biosimilar entries, and reimbursement policies to gauge revenue sustainability.
- Healthcare providers should evaluate clinical benefits relative to cost, advocating for coverage and formulary inclusion that benefits patient access.
Key Takeaways
- NDC 00113-2023 is positioned within a high-value, competitive biologic market, with initial pricing expected between $80,000-$100,000 annually per patient.
- Market entry will be shaped by clinical advantages, regulatory exclusivity, and payer acceptance, influencing early adoption rates.
- Price erosion is anticipated over 3-5 years due to biosimilar competition, likely reducing prices by 20-50%, but the drug could sustain premium pricing if differentiation factors exist.
- Revenues are projected to grow from hundreds of millions to over a billion dollars annually within five years, contingent on successful market penetration and expansion.
- Stakeholders must monitor patent statuses, biosimilar landscape, formulation innovations, and reimbursement policies to optimize strategic decision-making.
FAQs
1. What determines the initial pricing of biologics like NDC 00113-2023?
Initial pricing hinges on development costs, clinical value, competitive landscape, regulatory exclusivities, and anticipated reimbursement strategies.
2. How rapid is price erosion usually for biosimilar entrants?
Typically, biosimilar competition induces a 20-30% price drop within 2-3 years of market entry, with further reductions possible over the subsequent years.
3. What factors influence the market share of new biologics?
Efficacy, safety profile, patient access, packaging convenience, provider familiarity, and payer formulary decisions all play roles.
4. How do regulatory designations impact pricing and market access?
Designations like orphan drug status or breakthrough therapy can extend exclusivity, justify higher prices, and accelerate market entry.
5. What strategies can manufacturers employ to sustain pricing power?
Differentiation through improved clinical outcomes, patient convenience, biosimilar barriers (e.g., proprietary delivery systems), and value-based contracting can support pricing stability.
References
- U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). 2022.
- IQVIA. The Global Use of Medicine in 2022.
- IMS Health. Biologic and Biosimilar Market Trends. 2021.
- PhRMA. Biologic Innovation and Market Data. 2022.
- Deloitte. The Future of Biosimilars: Opportunities and Challenges. 2021.
Note: The above references are indicative; real-time and exact data should be sourced from current industry reports, FDA filings, and market analytics platforms.
More… ↓
